Neisseria meningitidis group B correlates of protection and assay standardization -: International meeting report Emory University, Atlanta, Georgia, United States, 16-17 march 2005

被引：161

作者：

Borrow, R.

Carlone, G. M.

Rosenstein, N.

Plikaytis, B.

Blake, M.

Feavers, I.

Martin, D.

Zollinger, W.

Robbins, J.

Aaberge, I.

Granoff, D. M.

Miller, E.

van Alphen, L.

Poolman, J.

Rappuoli, R.

Danzig, L.

Hackell, J.

Danve, B.

Caulfield, M.

Lambert, S.

Stephens, D.

机构：

[1] Manchester Royal Infirm, Vaccine Evaluat Unit, Hlth Protect Agcy, Manchester M13 9WZ, Lancs, England

[2] Ctr Dis Control & Prevent, Atlanta, GA USA

[3] US FDA, Bethesda, MD 20014 USA

[4] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England

[5] Inst Environm Sci, Porirua, New Zealand

[6] Walter Reed Army Inst Res, Washington, DC USA

[7] NICHHD, NIH, Bethesda, MD 20892 USA

[8] Norwegian Inst Publ Hlth, NO-0403 Oslo, Norway

[9] Childrens Hosp Oakland, Res Inst, Oakland, CA 94660 USA

[10] Hlth Protect Agcy Ctr Infect, London NW9 5EQ, England

[11] Netherlands Vaccine Inst, NL-3720 AL Bilthoven, Netherlands

[12] GlaxoSmithKline Biol, Rixensart, Belgium

[13] Chiron Vaccines, Siena, Italy

[14] Chiron Vaccines, Emeryville, CA 94608 USA

[15] Wyeth Vaccines, Pearl River, NY 10965 USA

[16] Sanofi Pasteur, F-69280 Marcy Letoile, France

[17] Merck & Co Inc, West Point, PA 19486 USA

[18] WHO, CH-1211 Geneva 27, Switzerland

[19] Emory Univ, Dept Med, Atlanta, GA 30322 USA

来源：

VACCINE | 2006年 / 24卷 / 24期

关键词：

D O I：

10.1016/j.vaccine.2006.03.091

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：5093 / 5107

页数：15

共 101 条

[61] IMMUNE-RESPONSE OF BRAZILIAN CHILDREN TO A NEISSERIA-MENINGITIDIS SEROGROUP-B OUTER-MEMBRANE PROTEIN VACCINE - COMPARISON WITH EFFICACY [J].

MILAGRES, LG ;

RAMOS, SR ;

SACCHI, CT ;

MELLES, CEA ;

VIEIRA, VSD ;

SATO, H ;

BRITO, GS ;

MORAES, JC ;

FRASCH, CE .

INFECTION AND IMMUNITY, 1994, 62 (10) :4419-4424

[62] Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story [J].

Miller, E ;

Salisbury, D ;

Ramsay, M .

VACCINE, 2001, 20 :S58-S67

[63] EXPRESSION OF THE L8 LIPOPOLYSACCHARIDE DETERMINANT INCREASES THE SENSITIVITY OF NEISSERIA-MENINGITIDIS TO SERUM BACTERICIDAL ACTIVITY [J].

MORAN, EE ;

BRANDT, BL ;

ZOLLINGER, WD .

INFECTION AND IMMUNITY, 1994, 62 (12) :5290-5295

[64]

NOKLEBY H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P95

[65] ASSESSMENT OF THE DIRECT EFFECTIVENESS OF BC MENINGOCOCCAL VACCINE IN RIO-DE-JANEIRO, BRAZIL - A CASE-CONTROL STUDY [J].

NORONHA, CP ;

STRUCHINER, CJ ;

HALLORAN, ME .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (05) :1050-1057

[66] From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease [J].

O'Hallahan, J ;

Lennon, D ;

Oster, P ;

Lane, R ;

Reid, S ;

Mulholland, K ;

Stewart, J ;

Penney, L ;

Percival, T ;

Martin, D .

VACCINE, 2005, 23 (17-18) :2197-2201

[67] MeNZB™:: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain [J].

Oster, P ;

Lennon, D ;

O'Hallahan, J ;

Mulholland, K ;

Reid, S ;

Martin, D .

VACCINE, 2005, 23 (17-18) :2191-2196

[68] Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland [J].

Perkins, BA ;

Jonsdottir, K ;

Briem, H ;

Griffiths, E ;

Plikaytis, BD ;

Hoiby, EA ;

Rosenqvist, E ;

Holst, J ;

Nokleby, H ;

Sotolongo, F ;

Sierra, G ;

Campa, HC ;

Carlone, GM ;

Williams, D ;

Dykes, J ;

Kapczynski, D ;

Tikhomirov, E ;

Wenger, JD ;

Broome, CV .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (03) :683-691

[69] Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing [J].

Pizza, M ;

Scarlato, V ;

Masignani, V ;

Giuliani, MM ;

Aricò, B ;

Comanducci, M ;

Jennings, GT ;

Baldi, L ;

Bartolini, E ;

Capecchi, B ;

Galeotti, CL ;

Luzzi, E ;

Manetti, R ;

Marchetti, E ;

Mora, M ;

Nuti, S ;

Ratti, G ;

Santini, L ;

Savino, S ;

Scarselli, M ;

Storni, E ;

Zuo, PJ ;

Broeker, M ;

Hundt, E ;

Knapp, B ;

Blair, E ;

Mason, T ;

Tettelin, H ;

Hood, DW ;

Jeffries, AC ;

Saunders, NJ ;

Granoff, DM ;

Venter, JC ;

Moxon, ER ;

Grandi, G ;

Rappuoli, R .

SCIENCE, 2000, 287 (5459) :1816-1820

[70] Statistical considerations for vaccine immunogenicity trials Part 1: introduction and bioassay design and analysis [J].

Plikaytis, BD ;

Carlone, GM .

VACCINE, 2005, 23 (13) :1596-1605

← 2 3 4 5 6 7 8 9 10 11 →